131 related articles for article (PubMed ID: 20052920)
21. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM
Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835
[TBL] [Abstract][Full Text] [Related]
22. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
Lodise TP; McKinnon PS; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 2007 Oct; 51(10):3731-3. PubMed ID: 17664322
[TBL] [Abstract][Full Text] [Related]
23. Failure of once-daily vancomycin for staphylococcal endocarditis.
Marik PE
Pharmacotherapy; 1998; 18(3):650-2. PubMed ID: 9620118
[TBL] [Abstract][Full Text] [Related]
24. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
Gomes DM; Ward KE; LaPlante KL
Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
[TBL] [Abstract][Full Text] [Related]
26. Medical treatment of staphylococcal infective endocarditis.
Bille J
Eur Heart J; 1995 Apr; 16 Suppl B():80-3. PubMed ID: 7671931
[TBL] [Abstract][Full Text] [Related]
27. A general survey of antibiotic treatment of staphylococcal septicaemia and endocarditis.
Watanakunakorn C
Scand J Infect Dis Suppl; 1983; 41():151-7. PubMed ID: 6589752
[TBL] [Abstract][Full Text] [Related]
28. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid.
Ruiz ME; Guerrero IC; Tuazon CU
Clin Infect Dis; 2002 Oct; 35(8):1018-20. PubMed ID: 12355391
[TBL] [Abstract][Full Text] [Related]
29. The role of vancomycin in the treatment paradigm.
Stevens DL
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S51-7. PubMed ID: 16323121
[TBL] [Abstract][Full Text] [Related]
30. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
31. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report.
Jongsma K; Joson J; Heidari A
J Antimicrob Chemother; 2013 Jun; 68(6):1444-5. PubMed ID: 23341127
[No Abstract] [Full Text] [Related]
32. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
Brown J; Brown KA; Forrest A
Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
[TBL] [Abstract][Full Text] [Related]
33. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
34. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.
Ho TT; Cadena J; Childs LM; Gonzalez-Velez M; Lewis JS
J Antimicrob Chemother; 2012 May; 67(5):1267-70. PubMed ID: 22311935
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
[TBL] [Abstract][Full Text] [Related]
36. [Use of vancomycin in the treatment of severe Staphylococcus aureus infection. Description of 3 cases].
Campelli A; Mantero E; Fabbri A; Nahum M; Ferraris R; Di Noto C
Minerva Med; 1984 Feb; 75(8):385-90. PubMed ID: 6709217
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
[TBL] [Abstract][Full Text] [Related]
38. Short-course combination and oral therapies of Staphylococcus aureus endocarditis.
Chambers HF
Infect Dis Clin North Am; 1993 Mar; 7(1):69-80. PubMed ID: 8463654
[TBL] [Abstract][Full Text] [Related]
39. Antibiotic therapy of nonenterococcal streptococcal and staphylococcal endocarditis: current regimens and some future considerations.
Karchmer AW
J Antimicrob Chemother; 1988 Apr; 21 Suppl C():91-106. PubMed ID: 3290187
[TBL] [Abstract][Full Text] [Related]
40. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis.
Gentry CA; Rodvold KA; Novak RM; Hershow RC; Naderer OJ
Pharmacotherapy; 1997; 17(5):990-7. PubMed ID: 9324187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
